Abstract
Tepotinib is an oral, once daily, highly selective, potent MET inhibitor approved for MET exon 14 (METex14) skipping NSCLC based mainly on Cohort A of the multi-cohort Phase II VISION study. We report primary analysis (>9-months’ follow-up) of the independent confirmatory Cohort C; data cut-off February 20, 2022.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
